5. Tanstuzumab treatment for breast cancer

Internal Medicine

Volumn 46, Issue 3, 2007, Pages 149-150

  Hatake, Kiyohiko ^a   Tokudome, Nahomi ^a   Ito, Yoshinori ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Breast cancer; Molecular target therapy; Tanstuzumab

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ALCOHOL CONSUMPTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; HEART DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MATERNAL AGE; MENARCHE; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; NUTRITIONAL STATUS; OBESITY; ONCOGENE NEU; OVERALL SURVIVAL; PATIENT MONITORING; PREMEDICATION; RISK FACTOR; SURVIVAL TIME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 33846896392     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.1783     Document Type: Article

References (1)

1. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with transtuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.